NCT00603863View on ClinicalTrials.gov

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

December 31, 2013

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

IMMU-107 (hPAM4)

90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks

Trial Locations (11)

10021

New York Presbyterian Hospital/Weill Cornell Medical Center, New York

10029

Mt. Sinai Medical Center, New York

19107

Thomas Jefferson University Medical Center, Philadelphia

19718

Christiana Care Health Services, Newark

27599

University of North Carolina, Chapel Hill

30322

Winship Cancer Institute/Emory University Hospital, Atlanta

33136

Sylvester Comprehensive Cancer Center, Miami

33169

Herbert Werthem College of Medicine/Jackson North Medical Center, Miami

33612

Moffit Cancer Center, Tampa

43210

Ohio State University Medical Center, Columbus

46526

Goshen Cancer Center, Goshen

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00603863 - Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | Biotech Hunter | Biotech Hunter